Integrated DNA Technologies, Inc.

• Booth: 1149

Integrated DNA Technologies (IDT) develops, manufactures, and markets products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development. The company's primary business is the production of custom oligonucleotides for molecular biology applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference.

Brands: Integrated DNA Technologies - IDT

 Press Releases

• Integrated DNA Technologies Launches New PrimeTime™ qPCR One-Step Master Mix with Exclusive Mutant Enzyme (Oct 06, 2022)

  With more than 35,000 combinations tested, IDT delivers unique master mix with proprietary blend to enrich endpoint fluorescence, optimize data confidence

  CORALVILLE, Iowa — (Sept. 26, 2022) — To support the growing need for an inhibitor resistant, high-performance master mix that allows for direct amplification of crude samples, Integrated DNA Technologies has launched the PrimeTime™ 1-Step 4X Broad-Range qPCR Master Mix. The unique, proprietary blend in this master mix is ideal for viral research and other gene expression applications and features a 4X concentrated formulation that eliminates the need for an extraction step. With its high endpoint florescence, IDT’s new one-step Master Mix provides researchers with a premium option that can save time and costs associated with doing extractions from viral transport media (VTM) prior to the amplification step, and it can boost confidence in data analysis.

  Using high-throughput screening, IDT scientists tested 35,000 component combinations of buffers, additives, and proprietary enzymes to ensure compatibility of all components. IDT scientists sought to address researcher pain points—from the need for reduced inhibitor effects, a higher concentration master mix blend and higher endpoint florescence for better data interpretation, to a flexible workflow that can be optimized for direct amplification from VTM. An inhibitor-resistant master mix was achieved through the discovery of enzymes engineered by IDT, one of which is exclusive to this master mix. The development of an enhancer solution included in the kit also acts to neutralize PCR inhibitor effects during reaction.

  “Recognizing that there are many master mix offerings in the market, our R+D team painstakingly worked to create a master mix that would solve some of the toughest challenges researchers face when using PCR applications,” said Steve Wowk, vice president of business unit and general management at IDT. “Leveraging our deep-rooted expertise in enzymology, we developed this Master Mix from the ground up to offer a new solution for today’s labs. Our goal is to help researchers working with viral pathogens and precious, rare samples who need a solution that can withstand biological contaminants that inhibit a PCR reaction and support the identification of their target in the lowest abundance possible, doing so with accuracy and consistency.”

  IDT’s 4X Master Mix will enable direct amplification of nasopharyngeal and saliva specimens tested directly out of VTM, with testing on other sample types ongoing. With the one-step RT-qPCR approach growing in popularity for high-speed, high-throughput screening, IDT customers can benefit from a differentiated master mix that offers a one-step RT-qPCR workflow and delivers results efficiently without compromising data insights.

  Accelerating Viral and Gene Expression Research

  The addition of the PrimeTime 1-Step 4X Broad-Range qPCR Master Mix enhances IDT’s existing portfolio of master mixes, enzymes, and reagents. IDT’s master mix offerings currently include the PrimeTime Gene Expression Master Mix—a 2X solution for probe-based qPCR in two-step RT-PCR experiments—and the PrimeTime One-Step RT-qPCR Master Mix, a 2X solution for probe-based qPCR in one-step RT-qPCR experiments. Since the company launched its PrimeTime qPCR Probes in 2005, the PrimeTime Probe & Primer kits in 2014, and its PrimeTime Master Mix in 2016, it has continued to expand its commercially produced solutions to enable scientists to achieve successful and consistent qPCR results. All IDT reagents undergo rigorous quality assessments for performance. For more information, or to place an order, click here.

  About IDT

  Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com and follow on Twitter, LinkedIn, Facebook, YouTube, and Instagram.

  Disclaimer: RUO - For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. GMP refers to products manufactured under ISO 13485: 2016 QMS. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

• Integrated DNA Technologies Launches Complete NGS Library Preparation Solution for Monkeypox (Oct 06, 2022)

  Leading genomics solutions provider debuts complete NGS library preparation to support the identification of novel monkeypox variants in response to growing researcher demands for viral surveillance solutions

  CORALVILLE, Iowa — (August 30, 2022) — With the World Health Organization declaring the monkeypox virus (MPXV) a Public Health Emergency of International Concern, and more than 47,000 total cases across 99 countries reported to date and growing, Integrated DNA Technologies (IDT) is supporting researchers conducting monkeypox surveillance with a new next generation sequencing (NGS) solution. Designed as part of IDT’s NGS Tech Access, the program is intended to accelerate innovation by enabling access to the most advanced research tools that are still in development.

  The xGen™ Monkeypox Virus Amplicon Panel is a complete NGS library preparation solution that supports the genotyping of MPXV within a sample. Leveraging IDT’s well-established NGS amplicon technology, the single-tube workflow creates overlapping amplicons, goes from sample to sequencer in 2.5 hours with up to 1,536 unique dual indexing (UDIs) for multiplexed sequencing, and helps pinpoint evolving epidemiological patterns. Orders can now be placed globally here.

  “With monkeypox cases continuing to rise, IDT responded with a new solution to support global efforts across the scientific community—because more discoveries can lead to better prevention and mitigation strategies,” said Steven Henck, vice president of R&D. “At IDT, we focus on using our team’s ability to deliver the right tools when they are needed because we believe that supporting and advancing the global research community benefits us all. The addition of the NGS monkeypox amplicon panel reinforces our mission to accelerate the pace of genomics and we’re proud to help researchers reliably identify and track the evolution of monkeypox.”

  NGS surveillance powered by super amplicons

  The infectious disease monitoring and surveillance field continues to face unprecedented pressure for accuracy and increased speed. IDT’s xGen Monkeypox Virus Amplicon Panel is a single-tube workflow that generates contiguous tiling of overlapping amplicons. Super amplicons enable novel variant discovery by maintaining genomic coverage even if a novel variant occurs under a primer binding site, which may disrupt a primer’s ability to bind. IDT tested the panel with commercially available monkeypox DNA and demonstrated coverage of positions 6760–190,905 (inverted-terminal repeats (ITRs) not included). Data can be generated from extracted viral DNA following a 2.5-hour workflow from viral DNA to libraries. The xGen Monkeypox Viral Amplicon Panel is also compatible with IDT Normalase™ technology.

  “As part of IDT’s NGS Tech Access Program, our team was able to acquire the xGen Monkeypox Virus Amplicon Panel and were enthused to see the promising sequencing data it generated for our research,” said Efrem Lim, Ph.D., associate professor at Arizona State University. “Given the importance of understanding infectious disease evolution, we recognize the outstanding work of partners like IDT who leverage their deep genomics expertise to provide cutting-edge NGS solutions that enable research, especially in our public health response to the monkeypox outbreak.”

  IDT expands its suite of monkeypox research solutions

  The monkeypox panel expands IDT’s xGen portfolio of NGS research solutions and was inspired by its SARS-CoV-2 amplicon panel, which successfully demonstrated coverage of new strains—like the Delta and Omicron variants—without the need for redesigning or versioning as the virus mutates. In addition to releasing its monkeypox virus NGS panel, IDT also is offering custom and pre-designed qPCR solutions for monkeypox research needs. For more information, visit IDT's website.

  About IDT

  Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com and follow on Twitter, LinkedIn, Facebook, YouTube, and Instagram.

  Disclaimers:

  RUO - For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. GMP refers to products manufactured under ISO 13485: 2016 QMS. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.